We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -1.79% | 27.50 | 27.00 | 28.00 | 29.00 | 27.50 | 28.00 | 326,997 | 15:09:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.59 | 27.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/11/2020 15:29 | there is some info here - still a bit vague. Skip to the question from Alexander Nowak near the end | thesasquatch | |
25/11/2020 15:21 | At last!! RENX get a 10% royalty on any sales revenue, there were a lot of different prices quoted a few months back ranging from $40 up to $100+... either way, the timing is very good with the vaccine rollout about to start, and with Bio Techne able to manufacture 10m a month straight off there should be considerable benefit. If they sell 10m tests over the course of the next 6 months at $40 per test that would bring in $40m of profit for RENX. Huge numbers are possible here. | 74tom | |
25/11/2020 15:00 | I've no idea what the margin for RENX is on each test or how long they will be needed for, but for a company with limited current revenues a few months of an extra few million could be very significant. Plus, our profile is raised ready for the next news | mad foetus | |
25/11/2020 14:48 | its a bit of a shame this didn't happen 3 months ago - it probably would have doubled the share price in the US but things take time! | nimbo1 | |
25/11/2020 14:47 | At US healthcare prices too... | mad foetus | |
25/11/2020 14:46 | Well, if bio techno can start shipping 10m units of the test a month that’ll make a monstrous difference to revenues here. | mr roper | |
25/11/2020 14:44 | weird world where US up 30% and aim 6%... go figure. However the US did fall 10% yesterday where as aim was flat. | nimbo1 | |
25/11/2020 14:43 | Almost like they knew that 8m quid line of stock was about to be shifted, then the news came...I love happy coincidences. | mr roper | |
25/11/2020 14:38 | Wakes wakey | nw99 | |
25/11/2020 14:32 | US quote up 34%...Mms here are sleeping | montynj | |
25/11/2020 13:32 | https://finance.yaho | montynj | |
25/11/2020 13:30 | https://finance.yaho | montynj | |
25/11/2020 13:29 | Added! CD | cambridgedon | |
25/11/2020 13:13 | From 38mins... | busterdog2 | |
25/11/2020 13:10 | In USA up 17% pre market | montynj | |
25/11/2020 13:01 | Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies. Just out! CD | cambridgedon | |
25/11/2020 10:27 | This trades in the USA expect it move higher later | nw99 | |
25/11/2020 09:29 | For a business update the Stifel call last week was pretty good. Lots in the pipeline here. Patience is the key. | mr roper | |
25/11/2020 08:05 | There is nothing new per se, but some interesting detail if you scroll further down for the Operational Update and Financial Results for the Three Months Ended September 30, 2020 | wan | |
25/11/2020 07:59 | Indeed, if they’re going to release quarterly commentary like that it needs to be accompanied by a secondary release with a business / trading update! Nobody is invested to read about cash burn... we would like to know how the KidneyIntelX roll out is going / what else is going on. | 74tom | |
25/11/2020 07:46 | Well I guess some people knew about the extremely monotone financial trading release. I guess there most be some serious us based regulatory reasons for writing such a downbeat commentary. | 2theduke | |
25/11/2020 00:47 | London South East managed to make it look like £10.7 million traded | welshborderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions